Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Kelley Gipson

Advancing health at The Jackson Laboratory

Over the course of 40 days on the International Space Station (ISS), researchers will determine the effect of microgravity on JAX’s Mighty Mice — genetically...

| By Kelley Gipson

Gov. Lamont names execs to workforce council

Connecticut Gov. Ned Lamont has named two dozen business and nonprofit executives, and several state and union officials, to a newly revamped group aimed at...

| By Kelley Gipson

Arvinas reports positive data re PROTAC® platform

Arvinas has announced a platform data update that includes initial safety, tolerability, and pharmacokinetic data from the company’s ongoing Phase 1 clinical trials of ARV-110...

| By Kelley Gipson

Alexion’s ULTOMIRIS® approved against AHUS

Alexion Pharmaceuticals reports that the FDA has approved ULTOMIRIS® (ravulizumab-cwvz) for the treatment of atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA)...

| By Kelley Gipson

Melinta gains BAXDELA® approval from FDA

Melinta Therapeutics reports that the FDA has approved BAXDELA® (delafloxacin) for the treatment of adult patients with community-acquired bacterial pneumonia (CABP) caused by designated susceptible...

| By Kelley Gipson

New Vanessa Hungarian office focuses on sun safety

Vanessa Research recently opened a branch office in Győr, Hungary. Located on the campus of Széchenyi István University, the office serves as an innovation hub...

| By Kelley Gipson

CaroGen adds immunologists to SAB

CaroGen Corporation has announced three distinguished additions to its Scientific Advisory Board: Professor Jack R Wands, MD, of Brown University Dr. Steve Projan, PhD, FAAM,...

| By Kelley Gipson

Three Governors release statement re cooperation

Governor Ned Lamont of Connecticut, Governor Gina Raimondo of Rhode Island, and Governor Charlie Baker of Massachusetts have released a joint statement regarding regional policy....

| By Kelley Gipson

SpringWorks starts trial re neurofibromas

SpringWorks reports that the first patient has been dosed in the Phase 2b ReNeu clinical trial evaluating mirdametinib (formerly PD-0325901), an oral, small molecule designed...

| By Kelley Gipson

Thetis wins NIH grant re chronic fatty liver disorder

Thetis Pharmaceuticals reports it has received a Fast-Track Small Business Innovation Research Grant from the National Institutes of Health (for development of an innovative new therapy,...